Illumina Acquires Pacific Biosciences for ~$1.2B with its Sequel SMRT Technology
Shots:
- Pacific to get $8.00/share making $1.2B as total deal value in cash- with its expected closure in Q2’19
- The acquisition is a focus to combine Pacific’s Sequel SMRT Technology for expansion of its biological discovery platform by bringing short- and long-read sequencing technologies together
- Sequel SMRT (Single-Molecule Real-Time) Technology is an automated system with integrated software- providing genetic information through long-read sequencing and accuracy
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
